Brian Park, PharmD

Drug Information Specialist https://www.medicalbag.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Medicine

HHS Authorizes Pharmacists to Administer Vaccines to Children

Brian Park, PharmD

August 26, 2020

HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.

Medicine

Mylan Launches Generic Version of Tecfidera for MS

Brian Park, PharmD

August 25, 2020

This is the first FDA-approved therapeutically equivalent, substitutable generic of Tecfidera.

Medicine

Autonomous AI System Cleared for Diabetic Retinopathy Screening

Brian Park, PharmD

August 21, 2020

EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.

Medicine

New Drug Application for Remdesivir Submitted

Brian Park, PharmD

August 19, 2020

Remdesivir is an investigational nucleotide analogue with broad-spectrum antiviral activity.

Medicine

Epinephrine Sublingual Film Gets Fast Track Status for Anaphylaxis

Brian Park, PharmD

August 18, 2020

AQST-108 is a sublingual film that delivers systemic epinephrine utilizing the Company’s proprietary technology.

Medicine

Capsaicin Patch Approved for Painful Diabetic Peripheral Neuropathy of the Feet

Brian Park, PharmD

August 14, 2020

The FDA has approved Qutenza® (capsaicin 8% patch; Averitas Pharma) for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet.

Medicine

FDA Wants More Data on Viaskin Peanut Allergy Patch

Brian Park, PharmD

August 12, 2020

The FDA noted that it could not approve the BLA due to concerns regarding “the impact of patch-site adhesion on efficacy and indicated the need for patch modifications, and subsequently a new human factor study.”

Medicine

Head Lice Treatment Xeglyze Gets FDA Approval

Brian Park, PharmD

August 4, 2020

The FDA has approved Xeglyze™ (abametapir; Dr. Reddy’s Laboratories) for the treatment of head lice infestation in patients aged 6 months and older.

Medicine

Early Data Show Investigational ChAdOx1 nCoV-19 Vaccine Safe, Immunogenic

Brian Park, PharmD

July 28, 2020

Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all evaluated participants.

Medicine

Immune Responses Observed in All Participants Dosed With Moderna’s COVID-19 Vaccine Candidate

Brian Park, PharmD

July 17, 2020

Participants demonstrated high levels of neutralizing antibody activity that exceeded those seen in convalescent sera obtained from persons with confirmed COVID-19.

Next post in Medicine